Drugs / IPI-493
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01193491 | Jun 2010 → Jul 2011 | hematopoietic and lymphoid cell neoplasm | Infinity Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT00724425 | Jul 2008 → Jul 2011 | cancer | Infinity Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IPI-493 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00724425 ↗ |
| Action | Inhibit | “IPI-493 is a potent inhibitor of heat shock protein 90 (Hsp90)” NCT00724425 ↗ |
| Route | Oral | “IPI-493 Orally Administered” NCT00724425 ↗ |